临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2014年
11期
1982-1984,1985
,共4页
支气管哮喘%布地奈德福莫特罗吸入剂%哮喘控制%肾上腺皮质功能%糖脂代谢
支氣管哮喘%佈地奈德福莫特囉吸入劑%哮喘控製%腎上腺皮質功能%糖脂代謝
지기관효천%포지내덕복막특라흡입제%효천공제%신상선피질공능%당지대사
asthma%budesonide and formoterol fumarate powder for inhalation%asthma control%adrenal function%glucose and lipid metabolism
目的：探讨长期应用布地奈德福莫特罗吸入剂(160μg/4．5μg )对支气管哮喘患者的控制作用及对肾上腺皮质功能、糖脂代谢的影响。方法将78例支气管哮喘患者随机分成治疗组和对照组,治疗组给予布地奈德福莫特罗吸入剂(160μg/4．5μg),每日两次,对照组按需应用沙丁胺醇吸入剂,口服茶碱缓释片。观察周期为一年。两组患者在治疗前1天(T0)、一个月(T1)、三个月(T3)、六个月(T6)、12个月(T12),分别给予哮喘控制测试( asthma control test,ACT)评分,呼气峰流速( peak expiratory flow, PEF)日变异率检查,分别抽血测皮质醇、促肾上腺素皮质激素(ACTH),空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三酯、总胆固醇。结果治疗组患者 ACT 评分高于对照组( P <0．05),治疗组患者 PEF 日变异率小于对照组( P <0．05)。治疗组与对照组皮质醇、ACTH、FPG、HbA1c、总胆固醇、甘油三酯之间的差异无统计学意义( P >0．05)。结论布地奈德福莫特罗吸入剂对支气管哮喘患者的控制有良好作用,长期应用对患者的肾上腺皮质功能、糖脂代谢无不良影响。
目的：探討長期應用佈地奈德福莫特囉吸入劑(160μg/4．5μg )對支氣管哮喘患者的控製作用及對腎上腺皮質功能、糖脂代謝的影響。方法將78例支氣管哮喘患者隨機分成治療組和對照組,治療組給予佈地奈德福莫特囉吸入劑(160μg/4．5μg),每日兩次,對照組按需應用沙丁胺醇吸入劑,口服茶堿緩釋片。觀察週期為一年。兩組患者在治療前1天(T0)、一箇月(T1)、三箇月(T3)、六箇月(T6)、12箇月(T12),分彆給予哮喘控製測試( asthma control test,ACT)評分,呼氣峰流速( peak expiratory flow, PEF)日變異率檢查,分彆抽血測皮質醇、促腎上腺素皮質激素(ACTH),空腹血糖(FPG)、糖化血紅蛋白(HbA1c)、甘油三酯、總膽固醇。結果治療組患者 ACT 評分高于對照組( P <0．05),治療組患者 PEF 日變異率小于對照組( P <0．05)。治療組與對照組皮質醇、ACTH、FPG、HbA1c、總膽固醇、甘油三酯之間的差異無統計學意義( P >0．05)。結論佈地奈德福莫特囉吸入劑對支氣管哮喘患者的控製有良好作用,長期應用對患者的腎上腺皮質功能、糖脂代謝無不良影響。
목적：탐토장기응용포지내덕복막특라흡입제(160μg/4．5μg )대지기관효천환자적공제작용급대신상선피질공능、당지대사적영향。방법장78례지기관효천환자수궤분성치료조화대조조,치료조급여포지내덕복막특라흡입제(160μg/4．5μg),매일량차,대조조안수응용사정알순흡입제,구복다감완석편。관찰주기위일년。량조환자재치료전1천(T0)、일개월(T1)、삼개월(T3)、륙개월(T6)、12개월(T12),분별급여효천공제측시( asthma control test,ACT)평분,호기봉류속( peak expiratory flow, PEF)일변이솔검사,분별추혈측피질순、촉신상선소피질격소(ACTH),공복혈당(FPG)、당화혈홍단백(HbA1c)、감유삼지、총담고순。결과치료조환자 ACT 평분고우대조조( P <0．05),치료조환자 PEF 일변이솔소우대조조( P <0．05)。치료조여대조조피질순、ACTH、FPG、HbA1c、총담고순、감유삼지지간적차이무통계학의의( P >0．05)。결론포지내덕복막특라흡입제대지기관효천환자적공제유량호작용,장기응용대환자적신상선피질공능、당지대사무불량영향。
Objective To explore the effect of budesonide and formoterol fumarate powder for inhalation on asthma control, adrenal function, glucose and lipid metabolism of patients with asthma. Methods 78 cases of asth-ma were randomly divided into the therapy group and the control group. The therapy group accepted budesonide and formoterol fumarate powder for inhalation (160μg/4. 5μg), twice a day, and the control group accepted albuerol in-halation-on-demand, theophylline sustained release tablets, 0. 1 gram, twice a day. The observation period was one year. All patients accepted asthma control test ( ACT) , peak expiratory flow ( PEF) rate variation, cortisol, ACTH, FPG, HbA1c, total cholesterol, and triglyceride. Results The ACT points were higher in the therapy group than in the control group (P<0. 05). The PEF rate variation was lower in the therapy group than in the control group (P<0. 05). There was no statistical difference in cortisol, ACTH, FPG, HbA1c, total cholesterol and triglyceride be-tween the two groups (P>0. 05). Conclusion Budesonide and formoterol fumarate powder for inhalation has excel-lent effect on asthma control. Long-term appliance has no harmful effect on adrenal function, glucose or lipid metabo-lism.
